https://www.selleckchem.com/products/biib129.html to describe an unusual case of necrotizing myositis in a rectus muscle, possibly related to BRAF inhibitor therapy. An 18-year old man with neurodegenerative Langerhans cell histiocytosis (LCH), recently started on the BRAF inhibitor dabrafenib, presented with right eye pain. Magnetic resonance imaging (MRI) orbits revealed a rectus muscle mass concerning for LCH recurrence or malignancy. Dabrafenib was stopped, and incisional biopsy of the mass was performed. The mass was absent on post-operative MRI, so no further treatment was pursued. Histopathologic evaluation was initially concerning for sarcoma, but on further analysis, appeared more consistent with necrotizing myositis. The mass did not recur, nor did the patient develop other signs or symptoms concerning for myositis or malignancy over a 24-month follow-up period. Necrotizing myositis has not been previously described in a rectus muscle or with BRAF inhibitor use, though myalgias and malignancies are established side effects. Necrotizing myositis may masquerade as sarcoma and should be on the differential diagnosis for a new mass in the setting of dabrafenib therapy. Necrotizing myositis has not been previously described in a rectus muscle or with BRAF inhibitor use, though myalgias and malignancies are established side effects. Necrotizing myositis may masquerade as sarcoma and should be on the differential diagnosis for a new mass in the setting of dabrafenib therapy. To describe multimodal imaging findings with focus on retinal and choroidal vascular features in acute macular neuroretinopathy (AMN). Three eyes from 3 patients (1 man, 2 women) with average age of 31 were included in this retrospective case series at a single institution. Each case showed petaloid hyporeflective areas on infrared images (IR) with variable levels of outer retinal defects on spectral domain optical coherence tomography (OCT). OCT angiography (OCT-A) images showed quantifiable